vs
Arlo Technologies, Inc.（ARLO）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Arlo Technologies, Inc.的季度营收约是再鼎医药的1.1倍（$141.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 16.2%），过去两年再鼎医药的营收复合增速更高（20.8% vs 6.7%）
Arlo Technologies是一家专注于无线监控摄像头研发生产的美国企业。在2018年8月于纽交所完成首次公开募股之前，Arlo一直是网件（Netgear）旗下的监控产品品牌，IPO之后网件仍持有该公司多数控制权。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ARLO vs ZLAB — 直观对比
营收规模更大
ARLO
是对方的1.1倍
$127.1M
营收增速更快
ZLAB
高出0.9%
16.2%
两年增速更快
ZLAB
近两年复合增速
6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.3M | $127.1M |
| 净利润 | $5.8M | — |
| 毛利率 | 46.4% | 51.0% |
| 营业利润率 | 3.3% | -54.6% |
| 净利率 | 4.1% | — |
| 营收同比 | 16.2% | 17.1% |
| 净利润同比 | 218.6% | — |
| 每股收益（稀释后） | $0.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARLOZLAB
| Q4 25 | $141.3M | $127.1M | ||
| Q3 25 | $139.5M | $115.4M | ||
| Q2 25 | $129.4M | $109.1M | ||
| Q1 25 | $119.1M | $105.7M | ||
| Q4 24 | $121.6M | $108.5M | ||
| Q3 24 | $137.7M | $101.8M | ||
| Q2 24 | $127.4M | $100.1M | ||
| Q1 24 | $124.2M | $87.1M |
净利润ARLOZLAB
| Q4 25 | $5.8M | — | ||
| Q3 25 | $6.9M | $-36.0M | ||
| Q2 25 | $3.1M | $-40.7M | ||
| Q1 25 | $-835.0K | $-48.4M | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-4.4M | $-41.7M | ||
| Q2 24 | $-11.6M | $-80.3M | ||
| Q1 24 | $-9.6M | $-53.5M |
毛利率ARLOZLAB
| Q4 25 | 46.4% | 51.0% | ||
| Q3 25 | 40.5% | 59.5% | ||
| Q2 25 | 44.9% | 60.6% | ||
| Q1 25 | 44.3% | 63.6% | ||
| Q4 24 | 36.9% | 61.5% | ||
| Q3 24 | 35.2% | 64.1% | ||
| Q2 24 | 36.8% | 64.9% | ||
| Q1 24 | 38.1% | 61.4% |
营业利润率ARLOZLAB
| Q4 25 | 3.3% | -54.6% | ||
| Q3 25 | 0.6% | -42.3% | ||
| Q2 25 | 1.5% | -50.3% | ||
| Q1 25 | -1.2% | -53.3% | ||
| Q4 24 | -5.0% | -62.6% | ||
| Q3 24 | -4.0% | -66.6% | ||
| Q2 24 | -10.0% | -76.0% | ||
| Q1 24 | -8.5% | -80.7% |
净利率ARLOZLAB
| Q4 25 | 4.1% | — | ||
| Q3 25 | 4.9% | -31.2% | ||
| Q2 25 | 2.4% | -37.3% | ||
| Q1 25 | -0.7% | -45.8% | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | -3.2% | -40.9% | ||
| Q2 24 | -9.1% | -80.2% | ||
| Q1 24 | -7.8% | -61.4% |
每股收益（稀释后）ARLOZLAB
| Q4 25 | $0.06 | $-0.05 | ||
| Q3 25 | $0.06 | $-0.03 | ||
| Q2 25 | $0.03 | $-0.04 | ||
| Q1 25 | $-0.01 | $-0.04 | ||
| Q4 24 | $-0.05 | $-0.09 | ||
| Q3 24 | $-0.04 | $-0.04 | ||
| Q2 24 | $-0.12 | $-0.08 | ||
| Q1 24 | $-0.10 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.4M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $127.8M | $715.5M |
| 总资产 | $310.5M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARLOZLAB
| Q4 25 | $146.4M | $689.6M | ||
| Q3 25 | $86.0M | $717.2M | ||
| Q2 25 | $71.2M | $732.2M | ||
| Q1 25 | $84.0M | $757.3M | ||
| Q4 24 | $82.0M | $779.7M | ||
| Q3 24 | $77.0M | $616.1M | ||
| Q2 24 | $62.9M | $630.0M | ||
| Q1 24 | $62.1M | $650.8M |
股东权益ARLOZLAB
| Q4 25 | $127.8M | $715.5M | ||
| Q3 25 | $129.2M | $759.9M | ||
| Q2 25 | $118.3M | $791.7M | ||
| Q1 25 | $103.4M | $810.8M | ||
| Q4 24 | $100.9M | $840.9M | ||
| Q3 24 | $96.9M | $667.7M | ||
| Q2 24 | $99.3M | $704.2M | ||
| Q1 24 | $99.9M | $762.2M |
总资产ARLOZLAB
| Q4 25 | $310.5M | $1.2B | ||
| Q3 25 | $350.9M | $1.2B | ||
| Q2 25 | $319.7M | $1.2B | ||
| Q1 25 | $296.6M | $1.2B | ||
| Q4 24 | $298.4M | $1.2B | ||
| Q3 24 | $312.4M | $985.3M | ||
| Q2 24 | $295.8M | $987.4M | ||
| Q1 24 | $289.8M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 3.43× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ARLOZLAB
| Q4 25 | $19.8M | $-26.0M | ||
| Q3 25 | $19.2M | $-32.0M | ||
| Q2 25 | $8.8M | $-31.0M | ||
| Q1 25 | $30.9M | $-61.7M | ||
| Q4 24 | $6.7M | $-55.8M | ||
| Q3 24 | $18.4M | $-26.8M | ||
| Q2 24 | $6.5M | $-42.2M | ||
| Q1 24 | $19.8M | $-90.1M |
自由现金流ARLOZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | $28.1M | $-63.2M | ||
| Q4 24 | $5.6M | $-58.4M | ||
| Q3 24 | $17.4M | $-28.2M | ||
| Q2 24 | $6.2M | $-42.9M | ||
| Q1 24 | $19.4M | $-91.1M |
自由现金流率ARLOZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | 23.6% | -59.9% | ||
| Q4 24 | 4.6% | -53.8% | ||
| Q3 24 | 12.6% | -27.7% | ||
| Q2 24 | 4.8% | -42.9% | ||
| Q1 24 | 15.7% | -104.5% |
资本支出强度ARLOZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | 2.4% | 1.5% | ||
| Q4 24 | 0.9% | 2.4% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.2% | 0.7% | ||
| Q1 24 | 0.3% | 1.1% |
现金转化率ARLOZLAB
| Q4 25 | 3.43× | — | ||
| Q3 25 | 2.79× | — | ||
| Q2 25 | 2.83× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARLO
| Subscriptions And Services | $89.4M | 63% |
| Products | $51.9M | 37% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
